Alzheimer’s affects over seven million Americans—a number expected to double by 2050. New FDA-approved drugs and early-detection blood tests give families hope, but government red tape still stands in the way. The Market Institute believes patients and doctors—not bureaucrats—should decide when to use lifesaving innovations. Empowering access to modern treatments isn’t just good policy—it’s the compassionate choice.
A new opinion piece by Market Institute President Charles Sauer in RealClearMarkets argues that policymakers should resist efforts to ban personalized pricing, warning that government intervention would undermine consumer choice and market efficiency. As retailers Read more…
A newly published paper in The Milbank Quarterly adds to the growing body of evidence that the federal 340B Drug Pricing Program has strayed far from its original purpose, strengthening the case for meaningful congressional Read more…
A new RealClearHealth op-ed by Dr. Craig Wax argues that if Congress is serious about reducing healthcare costs and increasing competition, lawmakers must reform one of the federal government’s biggest distortions: Medicare’s unequal payment system. Read more…
The American Innovation and Choice Online Act (AICOA) is back before Congress, and in a new RealClearMarkets op-ed, Market Institute Senior Fellow Norm Singleton argues lawmakers should finally let the legislation die. Comparing the bill Read more…
New RealClearHealth op-ed from Charles Sauer highlights why Washington must remove barriers to early diagnosis and treatment. Most Americans say they would want to know if they had Alzheimer’s disease years before symptoms appeared. Thanks Read more…
In a new column published in RealClearMarkets, Market Institute Senior Fellow Norm Singleton examines recent testimony from FTC Chair Andrew Ferguson and Commissioner Mark Meador before the Senate Commerce Committee. Singleton argues that Ferguson’s remarks Read more…
6151 Fuller Court #8
Alexandria, VA 22310
The Market Institute
info@marketinstitute.org